
Celularity Inc.
- Jurisdiction
United States - ISIN
US1511902041 (CELU )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€38.42M - Gross margin
68.8% - EBIT
-€40.63M - EBIT margin
-105.8% - Net income
-€63.47M - Net margin
-165.2%
Statement period: - (published )
Dividends
No dividend payouts